October 2012. Volume 8. Number 3

Additional use of prednisolone improves coronary artery outcomes in patients with severe Kawasaki disease

 
 
 
 
 
 
 
 
 
 
Rating: 4 (1 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al; RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613-20.
Reviewers: Molina Arias M1, González de Dios J2.
1Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 03/07/2012
Acceptance date: 24/07/2012
Publication date: 01/08/2012

Abstract

Author's conclusions: addition of prednisolone to the standard treatment of immunoglobulin and aspirin improves coronary artery outcomes in patients with severe Kawasaki disease in Japan.

Reviewers' conclusiones: findings from this trial show that early use of prednisolone and its maintenance in patients with severe Kawasaki disease might effectively control inflammation and vasculitis before failure of standard treatment occurs.

How to cite this article

Molina Arias M, González de Dios J. El uso adicional de prednisolona disminuye las anomalías coronarias en la enfermedad de Kawasaki grave. Evid Pediatr. 2012;8:55.

AVC | Critically appraised articles

Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al; RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613-20.
Reviewers: Molina Arias M1, González de Dios J2.
1Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
2Departamento de Pediatría. Hospital General Universitario de Alicante. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 03/07/2012
Acceptance date: 24/07/2012
Publication date: 01/08/2012

How to cite this article

Molina Arias M, González de Dios J. El uso adicional de prednisolona disminuye las anomalías coronarias en la enfermedad de Kawasaki grave. Evid Pediatr. 2012;8:55.

References

  1. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113:2606-12.
  2. Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu C, Matsubara T, et al. Kawasaki disease: a brief story. Pediatrics. 2000;106:E27.
  3. Newburguer JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663-75.
  4. Zhu BH, Lv HT, Sun L, Zhang JM, Cao L, Jia HL, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2012;171:571-8.
  5. Aizpurua P, Orejón de Luna G. Añadir corticoides intravenosos al tratamiento convencional con inmunoglobulinas y ácido acetilsalicílico no disminuye las complicaciones coronarias en la enfermedad de Kawasaki. Evid Pediatr. 2007;3:33.
01/08/2012

Linked Comment